Acurion, a San Diego, CA-based precision oncology technology company, closed its $4.3m seed financing round. 

The round was led by TK & Partners, with participation from Mesa Verde Venture Partners, The National Foundation for Cancer Research, the Asian Fund for Cancer Research, Bootstrap Ventures, institutional investors, impact funds, and healthcare executives.

The company intends to use the funds for clinical validation, platform development, regulatory preparation, and commercialization of OncoGaze™ toward broader clinical and research adoption.  

Led by Rick Fultz, CEO, Acurion is a precision oncology company developing AI-powered image analysis tools for biomarker detection that uncover clinically actionable insights from conventional pathology images. The OncoGaze™ platform extracts biomarker insights from routine pathology slides prepared during standard clinical care, enabling an instantaneous, scalable, and accessible approach to precision medicine.

Acurion’s technology builds on foundational work by co-founder and Chief Scientific Officer Ludmil Alexandrov, Ph.D., Professor of Cellular and Molecular Medicine at UC San Diego, whose work on mutational signatures has reshaped understanding of cancer origins and treatment response.  

The company expects to announce additional clinical collaborations and regulatory progress in the coming months.

source[FinSMEs]